Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Uterine Cervical Neoplasms 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 29Carboplatin 27durvalumab 21Specimen Handling 21Pemetrexed 18Cisplatin 17Paclitaxel 16atezolizumab 15Nivolumab 15Magnetic Resonance Spectroscopy 15osimertinib 11Radiosurgery 11Radiotherapy 10Immunoglobulin G 10Etoposide 10Docetaxel 10Disulfides 10Radiation 9Taxes 8Gemcitabine 8Biopsy 8Blood Specimen Collection 7Standard of Care 6Practice Guidelines as Topic 6Ipilimumab 6Surveys and Questionnaires 5Platinum 5Bronchoscopy 5Bevacizumab 5Ramucirumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lung Neoplasms × Tyrosine Kinase Inhibitors × Clear all
NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡